Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers
- 3 March 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (3) , 461-480
Abstract
Thirty years ago, the cloning of the first breast cancer susceptibility gene, BRCA1, marked a milestone in our understanding of hereditary breast and ovarian cancers. This discovery initiated extensive research into DNA repair mechanisms, BRCA1-associated tumorigenesis, and therapeutic interventions. Despite these advances, critical questions remain unanswered, such as the evolution of BRCA1-associated tumors and their tissue specificity. These issues hinder the development of effective treatment and prevention strategies, which ultimately aim to improve the quality of life for BRCA1 mutation carriers. In this review, we discuss current knowledge, identify existing gaps, and suggest possible avenues to tackle these challenges. Significance: Here, we explore the impact of three decades of BRCA1 research on the lives of mutation carriers and propose strategies to improve the prevention and treatment of BRCA1-associated cancer.Keywords
Funding Information
- KWF Kankerbestrijding (14516 and 14949)
- Oncode Institute
- Boehringer Ingelheim Fonds
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030M_219453)
- Artios Pharma
This publication has 228 references indexed in Scilit:
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAnnals of Oncology, 2022
- Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trialAnnals of Oncology, 2021
- Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiADAnnals of Oncology, 2021
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)Annals of Oncology, 2021
- Comprehensive molecular profiling broadens treatment options for breast cancer patientsCancer Medicine, 2020
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology, 2019
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation CarriersJAMA Oncology, 2018
- BRCA1‐associated mammary tumorigenesis is dependent on estrogen rather than progesterone signalingThe Journal of Pathology, 2018
- Prophylactic window therapy with the clinical poly(ADP‐ribose) polymerase inhibitor olaparib delays BRCA1‐deficient mammary tumour formation in miceThe Journal of Pathology, 2017
- Familial breast-ovarian cancer locus on chromosome 17q12-q23The Lancet, 1991